A Novel Follow-Up Model for Type 1 Diabetes in Children Leads to Higher Glycemic Control

Julia Vonasek1, Isabelle M Larsen2,3, Amar Nikontovic4

  • 1Pediatric Department, North Denmark Regional Hospital, Hjørring, Denmark.

Pediatric Diabetes
|April 30, 2025
PubMed

Insights

A new follow-up model significantly improved glycemic control in children with type 1 diabetes (T1D). The model increased well-regulated diabetes cases and lowered mean HbA1c levels, reducing complication risks.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Poor glycemic control in children with type 1 diabetes (T1D) increases the risk of long-term diabetic complications.
  • In 2016, only one-third of pediatric T1D patients at North Denmark Regional Hospital achieved well-regulated blood glucose levels (HbA1c ≤ 58 mmol/mol).

Purpose of the Study:

  • To evaluate the effectiveness of a novel, standardized follow-up model for improving glycemic control in pediatric T1D patients.
  • To assess the impact of the model on mean HbA1c levels in children with poorly regulated diabetes.

Main Methods:

  • A cohort of children aged 0-18 with T1D was studied.
  • A standardized follow-up protocol was implemented for patients with HbA1c > 58 mmol/mol, involving closer monitoring until glycemic control improved.

Main Results:

  • Following model implementation, the proportion of well-regulated T1D patients increased from one-third to two-thirds.
  • Poorly regulated diabetes (HbA1c > 75 mmol/mol) decreased from 19% to a few percent.
  • Mean HbA1c levels decreased by approximately 10 mmol/mol (0.8%) after the model's full implementation.

Conclusions:

  • The standardized follow-up model effectively increased the rate of well-regulated diabetes in pediatric T1D patients.
  • The intervention led to a significant reduction in mean HbA1c, indicating improved overall glycemic control.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
121
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
805
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
204
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
471